Navigation Links
Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
Date:5/28/2009

- Phase II clinical trial investigating the effectiveness of Intercell's Vaccine Enhancement (VE) Patch in combination with an injectable H5N1 pandemic influenza vaccine started today in the U.S.

- The study is fully funded by HHS - this is the second study conducted under a 5 year USD 128 m contract with the HHS

- Intercell's VE Patch may reduce the dosage and improve protection against an H5N1 pandemic influenza outbreak with only a single dose vaccine application

VIENNA and GAITHERSBURG, Md., May 28 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that it has advanced its efforts to develop its VE Patch to improve prevention of H5N1 pandemic influenza with the start of a Phase II clinical trial. The randomized and blinded study aims to determine the optimal dosage of both Intercell's VE Patch and the H5N1 influenza vaccine injected concomitantly, when combined with each other in a single dose regimen. The trial will be conducted in the U.S. and is expected to enroll 500 subjects at six study sites.

"The commencement of this Phase II study represents an important milestone in the clinical development of our VE Patch technology and in the partnership with HHS for use of our technology in providing potentially improved Pandemic Influenza vaccines," stated Thomas Lingelbach, COO of Intercell AG and CEO of Intercell USA. "The recent H1N1 influenza situation certainly highlights again the important global public health need in this arena. If we achieve our goal to achieve full protection with only a single dose plus patch this means an enormous logistical advantage making PanFlu immunization feasible."

The H5N1 pandemic influenza vaccine tested in the study comprises Intercell's VE Patch and an injectable H5N1 influenza vaccine manufactured by Solvay Biologicals, B.V. (Netherlands).

In 2008 Intercell announced the results of a first clinical trial wher
'/>"/>

SOURCE Intercell AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
2. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
3. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
4. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
5. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
6. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
7. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
9. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
10. Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R)
11. Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 2015 Der Pharmariese ... Abschlussbedingungen eine 100-prozentige Beteiligung am Unternehmen ZAO ... dieser Übernahme dringt Lupin in den russischen ... 765 Mrd. RUB im Jahr 2014 zu ... (IMS Health). Seit über einem Jahrzehnt verzeichnet ...
(Date:7/2/2015)... , July 3, 2015 ... del 100% de participación en ZAO "Biocom" en ... marca la incursión de Lupin en el mercado ... RUB en ventas, colocándolo como uno de los ... (IMS Health). Durante más de una década, el ...
(Date:7/2/2015)... VANCOUVER , July 2, 2015 /PRNewswire/ - ESSA Pharma ... its common shares have been approved for listing and trading ... ESSA will begin trading on NASDAQ on July ... TSX Venture Exchange under the symbol "EPI". As ... the NASDAQ, each of the Company,s outstanding special warrants issued ...
Breaking Medicine Technology:Lupin übernimmt Biocom aus Russland 2Lupin übernimmt Biocom aus Russland 3Lupin adquiere Biocom en Rusia 2Lupin adquiere Biocom en Rusia 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4
... OMAHA, Neb., March 5, 2012 /PRNewswire-iReach/ -- Database101.com, ... and mailing lists for small businesses and salespeople, ... with no minimum order; an added enhancement for marketers and ... for ways to save money while still finding new ways ...
... Varian Medical Systems, Inc., (NYSE: VAR ) ... InfiMed, Inc., a privately-owned, leading supplier of workstations including ... acquisition, which is expected to close in early April ... operate within Varian,s X-Ray Products segment.  The agreement provides ...
Cached Medicine Technology:Database101.com Offers Hot Sales Leads & Email Lists, ONLINE, with NO Minimum Order! 2Varian Medical Systems Announces Agreement to Acquire InfiMed, Inc. 2Varian Medical Systems Announces Agreement to Acquire InfiMed, Inc. 3
(Date:7/5/2015)... ... July 06, 2015 , ... City Sports, the Boston-based specialty sporting goods retailer, ... clinics for first-time triathletes this summer with ethos, the owner and operator of the ... 9, at 6:00 p.m. at the North End Greenway. The event will help new ...
(Date:7/5/2015)... , ... July 05, 2015 , ... ... products, announces the Weed Master, a landscaping invention that effectively removes weeds ... billion US dollars," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:7/5/2015)... (PRWEB) , ... July 05, 2015 , ... Doctors at ... a new IMRT/surgery combination may one day change the outlook for people with pleural ... it now. , Researchers report that five mesothelioma patients treated with 25Gy ...
(Date:7/4/2015)... ... July 04, 2015 , ... Earlier in 2015, on Feb. ... annual member survey , detailing the most common plastic surgery and minimally invasive ... raw data down into charts detailing demographic trends and regional preferences. With a ...
(Date:7/4/2015)... NY (PRWEB) , ... July 04, 2015 , ... When a hacker gains access to ... front and at the office. On Wednesday, July 1st, the FTC issued a scam ... as part of a verification process for a password reset instigated by the hacker. ...
Breaking Medicine News(10 mins):Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 3Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 2Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 3Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 4Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 5Health News:New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma 2Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 2Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 3Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 3Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 4
... 25 WellPoint, Inc. (NYSE:,WLP) announced today that ... Healthcare Conference on January 30, 2008. The presentation ... Time., All interested parties are invited to ... http://www.wellpoint.com and selecting the "Investor,Info" link. ...
... 25, 2008 Researchers from Mayo Clinic in ... stents (SEPSs) in the treatment of benign esophageal disease ... stent migration and few cases of long-term improvement. They ... patient populations and to guide future recommendations for the ...
... must pass more than lip service reform in wake ... The following is a,statement by Executive Director, Kurt Entsminger, ... are among the most restrictive,in the nation. To get ... by the symptoms of an illness like,schizophrenia to be ...
... Bill Novelli,made the following statement about next Monday,s vote on ... by the California State Senate,Committee on Health:, "On behalf ... the members of the State Senate Health Committee to pass ... Monday. ABX 1 1 represents a major step toward,ensuring that ...
... Inc. ("Assurant"),(NYSE: AIZ ), a premier provider of ... its board of,directors has declared a quarterly dividend of ... March 10, 2008 to shareholders of record as of,Feb. ... at the discretion of the,board of directors and will ...
... 25, 2008 --New York, NY-- Researchers in Belgium have ... with the capacity to generate new insulin-producing beta cells. ... the newfound progenitor cells may represent an obvious target ... researchers report in the Jan. 25 issue of the ...
Cached Medicine News:Health News:WellPoint Announces Appearance at Upcoming Conference 2Health News:Study examines self-expanding plastic stents in the treatment of benign esophageal conditions 2Health News:Study examines self-expanding plastic stents in the treatment of benign esophageal conditions 3Health News:Virginia Must Prize Mental Illness Treatment Over Psychosis 2Health News:Virginia Must Prize Mental Illness Treatment Over Psychosis 3Health News:Elusive pancreatic progenitor cells found in mice 2
Kit Nebulizer Small Volume Medication W/Pediatric Mask Mouthpiece 7FT O 2 Tubing...
... Nebulizer Small Volume Medication W/Adult Mask PT ... Tee Adapter , ,An advanced ... ,Provide fine particles with a tighter ... conventional nebulizers, ,Our AirLife™ brand Misty ...
Nebulizer Custom Kit...
... Respiratory Products, ,Westmed designs, manufacturers and ... and Respiratory professionals. Our mission is to ... clinician's ability to deliver quality medical care ... line. , ,Our web site is ...
Medicine Products: